Iron-binding characteristics of neuromelanin of the human substantia nigra

Biochemical Pharmacology

Volumn 66, Issue 3, 2003, Pages 489-494

  Double, Kay L ^a,b   Gerlach, Manfred ^b   Schünemann, Volker ^c   Trautwein, Alfred X ^c   Zecca, Luigi ^d   Gallorini, Mario ^e   Youdim, Moussa B H ^f   Riederer, Peter ^b   Ben Shachar, Dorit ^g  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF LÜBECK   (Germany)

^d Institute of Biomedical Technologies   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

^f TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^g RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Ferritin; Iron binding; M ssbauer spectroscopy; Neuromelanin; Parkinson's disease

Indexed keywords

IRON; NEUROMELANIN;

ARTICLE; BINDING SITE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; IRON BINDING CAPACITY; IRON BLOOD LEVEL; MOSSBAUER SPECTROSCOPY; NORMAL HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR AFFINITY; SUBSTANTIA NIGRA;

EID: 0041695547     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(03)00293-4     Document Type: Article

References (42)

1. Aime S., Bergamasco B., Biglino D., Digilio G., Fasano M., Giamello E., Lopiano L. EPR investigations of the iron domain in neuromelanin. Biochem. Biophys. Acta. 1361:1997;49-58.
2. 13C -NMR characterization of an insoluble proteinaceous fraction from substantia nigra of patients with Parkinson's disease Mov. Disord. 15:2000;977-981.
3. Aime S, Fasano M, Bergamasco B, Lopiano L, Quattrocolo G. Nuclear magnetic resonance spectroscopy characterization and iron content determination of human mesencephalic neuromelanin. In: Battistini L, Scarlato G, Caraceni T, Ruggieri S, editors. Advances in neurology. Philadelphia: Lippencott-Raven Publishers; 1996. p. 263-70.
4. Bartzokis G., Tishler T. MRI evaluation of basal ganglia ferritin iron and neurotoxicity in Alzheimer's and Huntington's disease. Cell Mol. Biol. (Noisy-le-Grand). 46:2000;821-833.
5. Ben-Shachar D., Riederer P., Youdim M.B.H. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57:1991;1609-1614.
6. Berg M.D., Gerlach M., Youdim M.B.H., Double K.L., Zecca L., Riederer P., Becker G. Brain iron pathways and their relevance to Parkinson's disease. J. Neurochem. 79:2001;225-236.
7. Bolzoni F., Giraudo S., Lopiano L., Bergamasco B., Fasano M., Crippa P.R. Magnetic investigations of human mesencephalic neuromelanin. Biochem. Biophys. Acta. 1586:2002;210-218.
8. Bridelli M.G., Tampellini D., Zecca L. The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett. 457:1999;18-22.
9. Castellani R., Siedlak S., Perry G., Smith M. Sequestration of iron by Lewy bodies in Parkinson's disease. Acta Neuropathol. 100:2000;111-114.
10. Chasteen N.D., Harrison P.M. Mineralization in ferritin: an efficient means of iron storage. J. Struct. Biol. 126:1999;182-194.
11. Dexter D.T., Wells F.R., Lees A.J., Agid F., Agid Y., Jenner P., Marsden C.D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
12. Double K., Gerlach M., Ben-Shachar D., Youdim M.B.H., Zecca L., Riederer P. Influence of neuromelanin on oxidative pathways within the human substantia nigra. Neurotox. Teratol. 24:2002;621-628.
13. Double K., Riederer P., Gerlach M. The significance of neuromelanin in Parkinson's disease. Drug News Develop. 12:1999;333-340.
14. Double K., Zecca L., Costo P., Mauer M., Greisinger C., Ito S., Ben-Shachar D., Bringmann G., Fariello R.G., Riederer P., Gerlach M. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75:2000;2583-2589.
15. Double KL, Gerlach M, Youdim MBH, Riederer P. Impaired iron homeostatsis in Parkinson's disease. In: Riederer P, Calne DB, editors. Advances in research on neurodegeneration. Vienna: Springer; 2000. p. 37-58.
16. Enochs W.S., Nilges M.J., Swartz H.M. Purified human neuromelanin, synthetic dopamine melanin as a potential model pigment, and the normal human substantia nigra: characterization by electron paramagnetic resonance spectroscopy. J. Neurochem. 61:1993;68-79.
17. Gerlach M., Double K.L., Youdim M.B.H., Riederer P. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotox. Res. 2:2000;99-114.
18. Gerlach M., Trautwein A.X., Zecca L., Youdim M.B.H., Riederer P. Mössbauer spectroscopic studies of purified human neuromelanin isolated from the substantia nigra. J. Neurochem. 65:1995;923-926.
19. Gibb W. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrastriatal projections and differential neuron susceptibility in Parkinson's disease. Brain Res. 581:1992;283-291.
20. Good P., Olanow C., Perl D. Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study. Brain Res. 593:1992;343-346.
21. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochem. Biophys. Acta. 1275:1996;161-203.
22. Hirsch E., Graybiel A., Agid Y. Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease. Nature. 28:1988;345-348.
23. Jellinger K., Kienzel E., Rumpelmair G., Riederer P., Stachellberger H., Ben-Shachar D., Youdim M.B.H. Iron-melanin complex in substantia nigra of parkinsonian brains: an X-ray microanalysis. J. Neurochem. 59:1992;1168-1171.
24. Kastner A., Hirsch E., Lejeune O., Javoy-Agid F., Rascol O., Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J. Neurochem. 59:1992;1080-1089.
25. Krol E.S., Liebler D.C. Photoprotective actions of natural and synthetic melanins. Chem. Res. Toxicol. 11:1998;1434-1440.
26. Kropf A.J., Bunker B.A., Eisner M., Moss S.C., Zecca L., Stroppolo A., Crippa P.A. XAFS studies of iron sites in synthetic and natural neuromelanin. Biophys. J. 75:1998;75.
27. Lopiano L., Chiesa M., Digilio D., Giraudo G., Bergamasco B., Fasano M. Q-band EPR investigations of neuromelanin in control and Parkinson's disease patients. Biochem. Biophys. Acta. 1500:2000;306-312.
28. Mochizuki H., Nishi K., Mizuno Y. Iron-melanin complex is toxic to dopaminergic neurons in nigrostriatal co-culture. Neurodegeneration. 2:1993;1-7.
29. Nau-Staudt K., Nau W.M., Haefliger I.O., Flammer J. Lipid peroxidation in porcine irises: dependence on pigmentation. Curr. Eye Res. 22:2001;229-234.
30. Offen D., Ziv I., Barzilai A., Gorodin S., Glater E., Hochman A., Melamed E. Dopaminemelanin induces apoptosis in PC12 cells: possible implications for the etiology of Parkinson's disease. Neurochem. Int. 31:1997;207-216.
31. Pilas B., Sarna T., Kalyanaraman B., Swartz H. The effect of melanin on iron associated decomposition of hydrogen peroxide. Free Radic. Biol. Med. 4:1988;285-293.
32. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
33. Rozanowska M., Sarna T., Land E., Truscott T. Free radical scavenging properties of melanin interaction of eu- and pheo-melanin models with reducing and oxidising radicals. Free Radic. Biol. Med. 26:1999;518-525.
34. Scalia M., Geremia E., Corsaro C., Santoro C., Baratta D., Sichel G. Lipid peroxidation in pigmented and unpigmented liver tissues: protective role of melanin. Pigment Cell Res. 3:1990;115-119.
35. Shima T., Sarna T., Swartz H., Stroppolo A., Gerbasi R., Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic. Biol. Med. 23:1997;110-119.
36. Sofic E., Riederer P., Heinsen H., Beckman H., Reynolds G.P., Hebenstreit G., Youdim M.B.H. Increased iron(III) and total iron content in post-mortem substantia nigra of parkinsonian brain. J. Neural Trans. 74:1988;199-205.
37. Youdim M.B.H., Ben-Shachar D., Riederer P. The enigma of neuromelanin in Parkinson's disease substantia nigra. J. Neural Trans. 43(Suppl.):1994;113-122.
38. Zareba M., Bober A., Korytowski W., Zecca L., Sarna T. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochem. Biophys. Acta. 1271:1995;343-348.
39. Zecca L., Gallorini M., Schünemann V., Trautwein A., Gerlach M., Riederer P., Vezzoni P., Tampellini D. Iron, neuromelanin and ferritin content in substantia nigra of normal subjects at different ages. Consequences for iron storage and neurodegenerative processes. J. Neurochem. 76:2001;1766-1773.
40. Zecca L., Mecacci O., Seraglia R., Parati E. The chemical characterization of melanin contained in substantia nigra of human brain. Biochim. Biophys. Acta. 1138:1992;6-10.
41. Zecca L., Shima T., Stroppolo A., Goj C., Battiston A., Gerbasi R., Sarna T., Swartz H.M. Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience. 73:1996;407-415.
42. Zecca L., Swartz H.M. Total and paramagnetic metals in human substantia nigra and its neuromelanin. J. Neural Trans. Park. Dis. Sect. 5:1993;203-213.